Systematic review: Hepatic fibrosis - Regression with therapy

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 10, 2008, Pages 1175-1187

  Zois, C D ^a   Baltayiannis, G H ^a   Karayiannis, P ^b   Tsianos, E V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; AMILORIDE; ANGIOTENSIN II ANTAGONIST; ANTHELMINTIC AGENT; ANTIGEN; ANTIOXIDANT; COLCHICEINE; COLCHICINE; CORTICOSTEROID DERIVATIVE; FARNESYLTHIOSALICYLIC ACID; GAMMA INTERFERON; GLUTATHIONE; INTERLEUKIN 10; INTERLEUKIN 12; MALOTILATE; OC 15161; PEGINTERFERON; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; QUERCETIN; RESVERATROL; RIBAVIRIN; S ADENOSYLMETHIONINE; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; WORM EGG ANTIGEN;

ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; CELL PROLIFERATION; CHRONIC LIVER DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CYTOKINE RELEASE; DISEASE COURSE; DRUG MECHANISM; ELASTOGRAPHY; EXTRACELLULAR MATRIX; FIBROGENESIS; FRACTAL ANALYSIS; HEPATITIS C; HEREDITY; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MONOTHERAPY; NONHUMAN; PARASITOSIS; PATHOGENESIS; PLASTICITY; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HUMANS; LIVER CIRRHOSIS; REMISSION INDUCTION;

EID: 54049141274     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03840.x     Document Type: Review

References (108)

1. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993 328: 1828 35.
2. Popper H, Elias H, Petty DE. Vascular patterns of the cirrhotic liver. Am J Clin Pathol 1952 22: 717 27.
3. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002 122: 1525 8.
4. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004 126: 1795 808.
5. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 2002 36: 200 9.
6. Knittel T, Kobold D, Saile B, et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999 117: 1205 21.
7. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000 275: 2247 50.
8. Friedman SL. The Hepatic Stellate Cell, Vol. 21. New York: Thieme, 2001.
9. Geerts A. History, heterogeneity, developmental biology and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001 21: 311 35.
10. Friedman SL. Hepatic stellate cells: protean, multifunctional and enigmatic cells of the liver. Physiol Rev 2008 88: 125 72.
11. Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998 29: 836 47.
12. Bachem MG, Riess U, Melchior R, Sell KM, Gressner AM. Transforming growth factors (TGF alpha and TGF beta 1) stimulate chondroitin sulfate and hyaluronate synthesis in cultured rat liver fat storing cells. FEBS Lett 1989 257: 134 7.
13. Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM. Modulation of transforming growth factor beta response and signalling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000 31: 1094 106.
14. Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000 279: G245 9.
15. Safadi R, Ohta M, Alvarez CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004 127: 870 82.
16. Pinzani M, Milani S, Grappone C, Weber FL Jr., Gentilini P, Abboud HE. Expression of platelet-derived growth factor in a model of acute liver injury. Hepatology 1994 19: 701 7.
17. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001 21: 397 416.
18. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001 21: 337 49.
19. Friedman SL. Stellate cells: a moving target in hepatic fibrogenesis. Hepatology 2004 40: 1041 3.
20. Magness ST, Bataller R, Yang L, Brenner DA. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004 40: 1151 9.
21. Lim YS, Lee HC, Lee HS. Switch of cadherin expression of E- to N-type during the activation of rat hepatic stellate cells. Histochem Cell Biol 2007 127: 149 60.
22. Sicklick JK, Choi SS, Bustamante M, et al. Evidence for epithelial-mesenchymal transitions in adult liver cells. Am J Physiol Gastrointest Liver Physiol 2006 291: G575 83.
23. Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979 76: 710 9.
24. Gressner AM. The cell biology of liver fibrogenesis-an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998 292: 447 52.
25. McGuire RF, Bissell DM, Boyles J, Roll FJ. Role of extracellular matrix in regulating fenestrations of sinusoidal endothelial cells isolated from normal rat liver. Hepatology 1992 15: 989 97.
26. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of stellate cells. Semin Liver Dis 2001 21: 373 84.
27. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998 102: 538 49.
28. Iredale JP. Hepatic stellate cell behaviour during resolution of liver injury. Semin Liver Dis 2001 21: 427 36.
29. Gentilini A, Marra F, Gentilini P, Pinzani M. Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like frowth factor-I in human hepatic stellate cells. J Hepatol 2000 32: 227 34.
30. Tangkijvanich P, Tam SP, Yee HF Jr. Wound-induced migration of rat hepatic stellate cells is modulated by endothelin-1 through rho-kinase-mediated alterations in the acto-myosin cytoskeleton. Hepatology 2001 33: 74 80.
31. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003 37: 1043 55.
32. Brun P, Castagliuolo I, Pinzani M, Palù G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2005 289: G571 8.
33. Viñas O, Bataller R, Sancho-Bru P, et al. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 2003 38: 919 29.
34. Kobayashi S, Seki S, Kawada N, et al. Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast-like cells. Cell Tissue Res 2003 311: 353 64.
35. Sandrin L, Tanter M, Gennisson JL, Catheline S, Fink M. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2002 49: 436 46.
36. Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003 29: 1705 13.
37. Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007 46: 628 34.
38. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005 41: 48 54.
39. Samonakis DN, Cholongitas E, Thalheimer U, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl 2007 13: 1305 11.
40. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004 39: 280 2.
41. Cholongitas E, Quaglia A, Samonakis D, et al. Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut 2006 55: 1789 94.
42. Moal F, Chappard D, Wang J, et al. Fractal dimension can distinguish models and pharmacologic changes in liver fibrosis in rats. Hepatology 2002 36: 840 9.
43. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997 113: 1609 16.
44. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007 45: 297 306.
45. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007 46: 32 6.
46. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006 43: 1317 25.
47. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004 3: 8.
48. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006 101: 547 55.
49. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004 10: 429 34.
50. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001 21: 437 51.
51. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997 349: 825 32.
52. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999 116: 378 86.
53. Smith BC, Gorve J, Guzail MA, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998 27: 1695 9.
54. Thorburn D, Curry G, Spooner R, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002 50: 248 52.
55. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005 115: 209 18.
56. Hammel P, Couvelard A, O'Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001 344: 418 23.
57. Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001 344: 452 4.
58. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124: 105 17.
59. Falize L, Guillygomarc'h A, Perrin A, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006 44: 472 7.
60. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004 40: 646 52.
61. Tome S, Lucey MR. Review article: current management of alcoholic liver disease. Aliment Pharmacol Ther 2004 19: 707 14.
62. Kershenobich D, Vargas F, Garcia-Tsao G, Perez-Tamayo R, Gent M, Rojkind M. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988 318: 1709 13.
63. Rodriguez L, Cerbón-Ambriz J, Muñoz ML. Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis. Arch Med Res 1998 29: 109 16.
64. Morgan TR, Weiss DG, Nemchausky B, et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005 128: 882 90.
65. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997 113: 884 90.
66. Poo JL, Feldman G, Erlinger S, et al. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Gastroenterology 1992 102: 1752 9.
67. Ala-Kokko L, Stenbäck F, Ryhänen L. Preventive effect of malotilate on carbon tetrachloride-induced liver damage and collagen accumulation in the rat. Biochem J 1987 246: 503 9.
68. Ala-Kokko L, Stenbäck F, Ryhänen L. Preventive effect of malotilate on dimethylnitrosamine-induced liver fibrosis in the rat. J Lab Clin Med 1989 113: 177 83.
69. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000 118: 655 60.
70. Bruck R, Shirin H, Hershkoviz R, et al. Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice. Gut 1997 40: 133 8.
71. Wynn TA, Cheever AW, Jankovic D, et al. An IL-12 based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995 376: 594 6.
72. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998 352: 1426 32.
73. Poynard T, McHutchinson J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002 122: 1303 13.
74. Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 2004 126: 1740 9.
75. Inagaki Y, Nemoto T, Kushida M, et al. Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 2003 38: 890 9.
76. Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression in experimental liver injury: implications for treatment of hepatic fibrosis. J Investig Med 1994 42: 660 70.
77. Lieber CS. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Adv Pharmacol 1997 38: 601 28.
78. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003 98: 2485 90.
79. Ramalho LN, Ramalho FS, Zucoloto S, et al. Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis. Hepatogastroenterology 2002 49: 1499 502.
80. Yoshiji H, Yoshii J, Ikenaka Y, et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 2002 37: 22 30.
81. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003 38: 1008 17.
82. Cho JJ, Hocher B, Herbst H, et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000 118: 1169 78.
83. Okazaki I, Watanabe T, Hozawa S, Niioka M, Arai M, Maruyama K. Reversibility of hepatic fibrosis: from the first report of collagenase in the liver to the possibility of gene therapy for recovery. Keio J Med 2001 50: 58 65.
84. Geerts A, Rogiers V. Sho-saiko-To: the right blend of traditional Oriental medicine and liver cell biology [editorial;comment]. Hepatology 1999 29: 282 4.
85. Sakaida I, Matsumura Y, Akiyama S, Hayashi K, Ishige A, Okita K. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-aminoacid-defined diet. J Hepatol 1998 28: 298 306.
86. Poynard T, McHutchinson J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000 32: 1131 7.
87. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003 38 (Suppl. 1 S38 53.
88. Friedman SL, Arthur MJ. Reversing hepatic fibrosis. Sci Med 2002 8: 194 205.
89. Desmet VJ. Comments on cirrhosis reversal. Dig Liver Dis 2005 37: 909 16.
90. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000 124: 1599 607.
91. Popper H. What are the major types of hepatic cirrhosis? In: Ingelfinger F, Relman A, Finland M, eds. Controversy in Internal Medicine. Philadelphia: WB Saunders, 1966: 233 43.
92. Ward NL, Haninec AL, Van Slyke P, et al. Angiopoietin-1 causes reversible degradation of the portal circulation in mice: implications for treatment of liver disease. Am J Pathol 2004 165: 889 99.
93. Friedman SL. Reversibility of hepatic fibrosis and cirrhosis-is it all hype? Nat Clin Pract Gastroenterol Hepatol 2007 4: 236 7.
94. Shimamatsu K, Wanless IR. Role of ischemia in causing apoptosis, atrophy and nodular hyperplasia in human liver. Hepatology 1997 26: 343 50.
95. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008 27: 542 51.
96. Rodriguez-Torres M, Rodrigues-Orengo JF, Rios-Bedoya CF, et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 2007 46: 613 9.
97. Cholongitas E, Papatheodoridis GV. Review article: novel therapeutic options for chronic hepatitis C. Aliment Phrmacol Ther 2008 27: 866 84.
98. Weng HL, Wang BE, Jia JD, et al. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 2005 3: 819 28.
99. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000 132: 517 24.
100. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus (HCV) related cirrhosis. Hum Pathol 2004 35: 107 12.
101. Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006 37: 1519 26.
102. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997 127: 981 5.
103. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology 1995 21: 1232 7.
104. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995 21: 1238 47.
105. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003 38: 1449 57.
106. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996 24: 289 93.
107. Ratziu V, Frederic C, Heurtier A, et al. LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005 128: 1898 906.
108. Regev A, Berho M, Jeffers LJ, et al. Sampling error and interobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002 97: 2614 8.